Bing

SEARCH HISTORY

Vienna, VA, April 11, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and six month warrants in a "best efforts" underwritten public offering. The offering is ...
The Wall Street Transcript · 4/11/2014
HONG KONG, Apr 23, 2015 - (ACN Newswire) - Recently, China Everbright Limited ("CEL", stock code: 165.HK) and Sinowel Enterprise Group ("Sinowel") announced the signing of a strategic partnership agreement to start their co-operation towards the …
ACN Newswire · 4/23/2015
The following stocks have gapped below the previous day’s close. B Communications Ltd. (BCOM) had a gap down today of (2.31) points or -13.01 percent below its previous close of $17.75. The company traded at $16.68 – 1.07 (6.03 percent). Kelso ...
Fx Pips · 1/6/2015
More from Bing News
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has priced an underwritten public offering of units of common stock and warrants at a price of $0.63 per unit for gross …
Business Wire · 12/19/2013
CEL-SCI Corporation (NYSEMKT:CVM), is a late stage oncology company. It has announced that the company has now priced its “best efforts” underwritten PO of units of its common stock & warrants at a per unit price of $1.40, for the gross ...
Nautilus Investment Strategies Magazine · 4/18/2014
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 5,238,095 shares of common stock and warrants to purchase an aggregate of ...
News-Medical · 12/27/2013
NEW YORK, NY / ACCESSWIRE / April 23 ... for a recent IPO that sent the stock soaring at its opening, priced at $17 and opening at $32. Cel-Sci has been unfairly ignored in this race for cancer immunotherapy drugs. This stock has seen momentum and I ...
BayStreet · 4/23/2015
CEL-SCI Corporation (NYSE MKT: CVM) (“CEL SCI” or the “Company”) today announced that the Italian Medicines Agency (AIFA) has authorized the Company to commence patient enrollment for its ongoing Phase 3 trial of its investigational …
Financial Content · 5/13/2015
TheStreet downgraded shares of Cellcom Israel (NYSE:CEL) from a hold rating to a sell rating in a report issued on Tuesday. TheStreet has also updated their ratings on a number of other information technology stocks in the last week. The firm downgraded ...
Mideast Times · 4/17/2015
This article was originally distributed via SproutNews. SproutNews, WorldNow and this Site make no warranties or representations in connection therewith. NEW YORK, NY / ACCESSWIRE / April 23, 2015 / Cancer immunotherapy is scorching hot. At no …
6 WECT · 4/23/2015